Emerging Innovations in Post-Event Lipid Management for ASCVD

The panelists conclude by examining emerging innovations in post-event lipid management aimed at improving outcomes for patients with ASCVD. They highlight a shift toward earlier initiation of intensive LDL-C lowering—beginning during hospitalization or soon after discharge—to prevent recurrent events during the period of highest vulnerability. The experts discuss the growing use of siRNA-based therapies such as inclisiran and the development of next-generation PCSK9-targeting agents that combine potency with simplified dosing schedules to improve adherence. They also note increasing interest in combination approaches, including pairing statins with bempedoic acid or PCSK9-directed therapies for sustained LDL-C control. The conversation underscores the importance of integrating lipid management into hospital discharge planning and ensuring seamless transitions to outpatient care. The panelists express optimism that continued innovation—coupled with improved access and education—will help clinicians achieve earlier, more durable LDL-C reduction and ultimately reduce recurrent ASCVD events.